Povezanost osteokalcina i energetskog metabolizma kod gojaznosti
Sažetak
Apstrakt
Uvod/Cilj. Brojna dosadašnja saznanja ukazala su na postojanje uloge osteokalcina, tradicionalnog parametra metaboličke aktivnosti kosti, u regulaciji metabolizma ugljenih hidrata. Cilj ove studije bio je da se utvrdi postojanje relacije između osteokalcina i izračunatih parametara procene stepena insulinske osetljivosti/rezistencije i sekretorne sposobnosti pankreasa kod gojaznih, nedijabetičnih ispitanika. Metode. Studijom je obuhvaćeno 57 gojaznih osoba (11 muškaraca i 46 žena) (indeks telesne mase – ITM: 41,03 ± 6,61 kg/m²) i 48 zdravih, normalno uhranjenih ljudi (ITM : 23,15 ± 2,04 kg/m²) koji odgovaraju ispitivanoj grupi, po starosti i polu. Svim ispitanicima izmerena je glukoza i insulin u toku dvočasovnog testa oralnog opterećenja glukozom (OGTT), osteokalcin i izračunate vrednosti Homeostatic Model Assessment (HOMA) indeksa (HOMA-IR, HOMA-B%), EISI (indeksa insulinske osetljivosti), (estimated first phase) i EFP (estimated second phase) druge faze (ESP) i procena sekretarnog kapaciteta pankreasnih ćelija druge faze (ESP). Koncentracija osteokalcina merena je u serumu, elektrohemiluminescentnom (ECLIA) metodologijom. Rezultati. Utvrđene su statistički značajno niže vrednosti osteokalcina u grupi gojaznih (ITM = 24,72 ± 9,80 vs 33,31 ± 10,89 ng/mL; p < 0,01). Linearnom korelacionom analizom dobijen je visok stepen pozitivne povezanosti osteokalcina sa EISI (r = 0,340; p < 0,01). Inverzna korelacija utvrđena je između osteokalcina i HOMA-IR (r = -0,276; p < 0,01), HOMA-B% (r = -0,337; p < 0,01), EFP (r = -0,332; p < 0,01) i ESP (r = -0,266; p < 0,01). ITM i osteokalcin imaju značajnu inverznu predikciju sa EISI i HOMA-IR, ali je nivo predikcije ITM bitno viši u odnosu na osteokalcin. Zaključak. Uticaj osteokalcina na sistem glikoregulacije je evidentan, ali je njegov udeo u tome bitno manji u odnosu na gojaznost i druge činioce povezane sa gojaznošću. Zbog toga se pri proceni mesta i uloge osteokalcina u glikoregulaciji, uvek mora imati u vidu da je osteokalcin, kao sistemski medijator, samo jedan od brojnih drugih faktora, pri čemu neki od njih, ispoljavaju dominantnije uticaje od osteokalcina.
Reference
REFERENCES
Lebovitz HE. Insulin resistance: Definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109 Suppl 2: S135‒48.
Ionescu-Tirgoviste C, Ioacara S, Guja C, Sabau S, Lichiardopol R, Mi¬hai A, et al. A pathophysiological approach to metabolic syn¬drome using factor analysis in an adult Romanian popula-tion. Arch Physiol Biochem 2006; 112(3): 182‒8.
Fukumoto AS, Martin J. Bone as an endocrine organ. Trend En-docrinol Metab 2009; 20(5): 230‒6.
Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trend Endocrinol Metab 2008; 19(5): 161‒6.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130(3): 456‒69.
Karsenty G. Convergence between bone and energy homeosta-ses: leptin regulation of bone mass. Cell Metab 2006; 4(5): 341‒8.
Cvijovic G, Micić G, Kendereški A, Zoric S, Polovina S, Šumarac DM, et al. Glucose and bone metabolism – potential interac-tions. Acta Clin 2014; 14(3): 68‒72. (Serbian)
Motyl KJ, McCabe LR, Schwartz AV. Bone and glucose metabo-lism: A two-way street. Arch Biochem Biophys 2010; 503(1): 2‒10.
Wiecek A, Adamczak M, Chudek J. Adiponectin: an adipokine with unique metabolic properties. Nephrol Dial Transplant 2007; 22(4): 981‒8.
Aoki A, Muneyuki T, Yoshida M, Munakata H, Ishikawa SE, Suga¬wara H, et al. Circulating osteocalcin is increased in early-stage diabetes. Diabetes Res Clin Pract 2011; 92(2): 181‒6.
Caballero B. The global epidemic of obesity: an overview. Epi-de¬miol Rev 2007; 29: 1‒5.
Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van HT, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23(3): 295‒301.
HOMA calculator software. Available from: https://www.dtu.ox.ac.uk/homacalculator/
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412‒9.
Hardy OT, Czech MP, Corvera S. What causes the insulin resis-tance underlying obesity. Curr Opin Endocrinol Diabetes Ob-es 2012; 19(2): 81‒7.
Cifuentes M, Johnson MA, Lewis RD, Heymsfield SB, Chowdhury HA, Modlesky CM, et al. Bone turnover and body weight rela-tionships differ in normal weight compared to with havier postmenopausal women. Osteporosis Int 2003; 14: 116‒22.
Lucey AJ, Pashos GK, Thorsdottir I, Martinez JA, Cashman KD, Kiely M. Young overweight and obese women with lower cir-culating osteocalcin concentrations exibit higher insulin resis-tance and concentrations of c-reactive protein. Nutr Res 2013; 33(1): 67‒75.
Matthaei S, Stumvoll M, Kellerer M, Häring HU. Pathophysi-ology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21(6): 585‒618.
Sarkar PD, Choudhury AB. Relationships between serum osteo-calcin levels versus blood glucose, insulin resistance and mark-ers of systemic inflammation in central Indian type 2 diabetic patients. Eur Rev Med Pharmacol Sci 2013; 17(12): 1631‒5.
Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insu¬lin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sec-tional study in Malmö, Sweden. Diabet Med 2000; 17(4): 299‒307.
Saleem U, Mosley TH, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 2010; 30(7): 1474‒8.
Yamamuchi T, Kamon J, Ito Y, Tsuchida A, Yokomiyo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423(6941): 762‒9.
Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differen-tially regulates bet cell and adipocyte gene expression and af-fects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 2008; 105(13): 5266‒70.
Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone 2011; 48(4): 720‒5.
Kanazawa I. Osteocalcin as a hormone regulating glucose me-tabolism. World J Diabet 2015; 6(18): 1345‒54.